Filing Flows › Puma Biotechnology (PBYI) › Q1 2025
Puma Biotechnology (PBYI) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Puma Biotechnology (PBYI) reported revenue of $46.0M for the first quarter 2025 (Q1 2025), +5% from a year earlier and -22% from the quarter before. Operating margin was 8.7%, net earnings $3.0M (6.5% of revenue).
Puma Biotechnology, Q1 2025: revenue $46.0M (+5% year over year), operating margin 8.7%, net earnings $3.0M, operating cash flow $3.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $46.0M | -22% | +5% |
| Operating profit | $4.0M | -70% | — |
| Net earnings | $3.0M | -85% | — |
| Operating cash flow | $3.6M | -77% | -68% |
| Free cash flow | $3.6M | -77% | -68% |
What changed
Revenue was $46.0M in Q1 2025, up 5% year over year and down 22% from the previous quarter. Product was the largest line at 94% of revenue. Product added $2.8M year over year (up 7%), 126% of the total change. Royalty declined 17%.
Operating profit was $4.0M, a 8.7% margin (up 13.9 points year over year). Total costs fell 9% while revenue rose 5%. Net earnings were $3.0M. The effective tax rate was 9.0%.
Operating cash flow was $3.6M (down 68% year over year), 121% of net earnings. Non-cash charges added back $2.8M of depreciation and amortization and $2.0M of share-based compensation. Working capital and other items used $4.2M. Capital expenditures of $61K left free cash flow of $3.6M.
Questions
What was Puma Biotechnology's revenue in the first quarter 2025?
Puma Biotechnology (PBYI) reported revenue of $46.0M for the first quarter 2025 (Q1 2025), +5% from a year earlier and -22% from the quarter before.
Was Puma Biotechnology profitable in the first quarter 2025?
Operating profit was $4.0M (8.7% of revenue) and net earnings $3.0M.
Source: Puma Biotechnology 10-Q on SEC EDGAR.